Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (71-80 of 802) with videos related to

Pageof 81
Sort By:
Haematologica|July 6, 2005
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disordersMario Cazzola, Radek Skoda
Evidence-Based Medicine|September 17, 2016
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patientsMario Cazzola, Paola Rogliani
British Journal of Haematology|April 27, 2017
Advances in understanding the pathogenesis of familial myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
American Journal of Hematology|August 30, 2008
Prognostic relevance of anemia in myelodysplastic syndromesMario Cazzola, Luca Malcovati
Hematology/Oncology Clinics of North America|April 3, 2010
Prognostic classification and risk assessment in myelodysplastic syndromesMario Cazzola, Luca Malcovati
Pulmonary Pharmacology & Therapeutics|May 18, 2010
Biomarkers in COPDMario Cazzola, Giuseppe Novelli
Blood|December 29, 2016
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
Drugs|April 3, 2014
Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefitMario Cazzola, Andrea Segreti
Journal of Comparative Effectiveness Research|August 26, 2017
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary diseaseMario Cazzola, Paola Rogliani
Pulmonary Pharmacology & Therapeutics|September 15, 2015
Combination treatment in asthma: Reviewing old and new optionsAlberto Papi, Mario Cazzola
Pageof 81

Showing results (71-80 of 802) with videos related to

Sort By:
Pageof 81
Haematologica|July 6, 2005
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disordersMario Cazzola, Radek Skoda
Evidence-Based Medicine|September 17, 2016
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patientsMario Cazzola, Paola Rogliani
British Journal of Haematology|April 27, 2017
Advances in understanding the pathogenesis of familial myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
American Journal of Hematology|August 30, 2008
Prognostic relevance of anemia in myelodysplastic syndromesMario Cazzola, Luca Malcovati
Hematology/Oncology Clinics of North America|April 3, 2010
Prognostic classification and risk assessment in myelodysplastic syndromesMario Cazzola, Luca Malcovati
Pulmonary Pharmacology & Therapeutics|May 18, 2010
Biomarkers in COPDMario Cazzola, Giuseppe Novelli
Blood|December 29, 2016
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasmsElisa Rumi, Mario Cazzola
Drugs|April 3, 2014
Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefitMario Cazzola, Andrea Segreti
Journal of Comparative Effectiveness Research|August 26, 2017
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary diseaseMario Cazzola, Paola Rogliani
Pulmonary Pharmacology & Therapeutics|September 15, 2015
Combination treatment in asthma: Reviewing old and new optionsAlberto Papi, Mario Cazzola
Pageof 81